Cargando…

Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients

Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: De Logu, Francesco, Galli, Francesca, Nassini, Romina, Ugolini, Filippo, Simi, Sara, Cossa, Mara, Miracco, Clelia, Gianatti, Andrea, De Giorgi, Vincenzo, Rulli, Eliana, Cossu, Antonio, Massi, Daniela, Mandalà, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922113/
https://www.ncbi.nlm.nih.gov/pubmed/33671367
http://dx.doi.org/10.3390/cells10020422
_version_ 1783658615180099584
author De Logu, Francesco
Galli, Francesca
Nassini, Romina
Ugolini, Filippo
Simi, Sara
Cossa, Mara
Miracco, Clelia
Gianatti, Andrea
De Giorgi, Vincenzo
Rulli, Eliana
Cossu, Antonio
Massi, Daniela
Mandalà, Mario
author_facet De Logu, Francesco
Galli, Francesca
Nassini, Romina
Ugolini, Filippo
Simi, Sara
Cossa, Mara
Miracco, Clelia
Gianatti, Andrea
De Giorgi, Vincenzo
Rulli, Eliana
Cossu, Antonio
Massi, Daniela
Mandalà, Mario
author_sort De Logu, Francesco
collection PubMed
description Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. Materials and Methods: digital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM ≥ 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort. Results: in the training cohort, 100 Stage II–III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4(+) intratumoral T-cells (aHR [100 cell/mm(2) increase] 0.98, 95%CI 0.95–1.00, p = 0.041) and CD163(+) inner peritumoral (aHR [high vs. low] 0.56, 95%CI 0.32–0.99, p = 0.047). A statistically significant longer DFS (aHR [high-high vs. low-low] 0.52, 95%CI 0.28–0.99, p = 0.047) and overall survival (OS) (aHR [high-high vs. low-low] 0.39, 95%CI 0.18–0.85, p = 0.018) was found in patients with a high density of both intratumoral CD8(+) T-cells and CD68(+) macrophages as compared to those with low density of both intratumoral CD8(+) T-cells and CD68(+) macrophages. Consistently, in the validation cohort, patients with high density of both intratumoral CD8(+) and CD3(+) T-cells were associated to a statistically better DFS (aHR[high-high vs. low-low] 0.24, 95%CI 0.10–0.56, p < 0.001) and those with high density of both intratumoral CD8(+) and CD68(+) were associated to a statistically longer OS (aHR[high-high vs. low-low] 0.28, 95%CI 0.09–0.86, p = 0.025). Conclusion: our findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II–III melanoma patients.
format Online
Article
Text
id pubmed-7922113
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79221132021-03-03 Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients De Logu, Francesco Galli, Francesca Nassini, Romina Ugolini, Filippo Simi, Sara Cossa, Mara Miracco, Clelia Gianatti, Andrea De Giorgi, Vincenzo Rulli, Eliana Cossu, Antonio Massi, Daniela Mandalà, Mario Cells Article Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. Materials and Methods: digital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM ≥ 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort. Results: in the training cohort, 100 Stage II–III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4(+) intratumoral T-cells (aHR [100 cell/mm(2) increase] 0.98, 95%CI 0.95–1.00, p = 0.041) and CD163(+) inner peritumoral (aHR [high vs. low] 0.56, 95%CI 0.32–0.99, p = 0.047). A statistically significant longer DFS (aHR [high-high vs. low-low] 0.52, 95%CI 0.28–0.99, p = 0.047) and overall survival (OS) (aHR [high-high vs. low-low] 0.39, 95%CI 0.18–0.85, p = 0.018) was found in patients with a high density of both intratumoral CD8(+) T-cells and CD68(+) macrophages as compared to those with low density of both intratumoral CD8(+) T-cells and CD68(+) macrophages. Consistently, in the validation cohort, patients with high density of both intratumoral CD8(+) and CD3(+) T-cells were associated to a statistically better DFS (aHR[high-high vs. low-low] 0.24, 95%CI 0.10–0.56, p < 0.001) and those with high density of both intratumoral CD8(+) and CD68(+) were associated to a statistically longer OS (aHR[high-high vs. low-low] 0.28, 95%CI 0.09–0.86, p = 0.025). Conclusion: our findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II–III melanoma patients. MDPI 2021-02-17 /pmc/articles/PMC7922113/ /pubmed/33671367 http://dx.doi.org/10.3390/cells10020422 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Logu, Francesco
Galli, Francesca
Nassini, Romina
Ugolini, Filippo
Simi, Sara
Cossa, Mara
Miracco, Clelia
Gianatti, Andrea
De Giorgi, Vincenzo
Rulli, Eliana
Cossu, Antonio
Massi, Daniela
Mandalà, Mario
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title_full Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title_fullStr Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title_full_unstemmed Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title_short Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
title_sort digital immunophenotyping predicts disease free and overall survival in early stage melanoma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922113/
https://www.ncbi.nlm.nih.gov/pubmed/33671367
http://dx.doi.org/10.3390/cells10020422
work_keys_str_mv AT delogufrancesco digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT gallifrancesca digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT nassiniromina digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT ugolinifilippo digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT simisara digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT cossamara digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT miraccoclelia digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT gianattiandrea digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT degiorgivincenzo digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT rullieliana digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT cossuantonio digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT massidaniela digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients
AT mandalamario digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients